Bausch Lomb Corporation is an eye health company. Its product portfolio includes Biotrue(R) and renu(R) multi-purpose solutions, Biotrue(R) ONEday daily disposable contact lenses, LUMIFY(R) redness reliever eye drops, PreserVision(R) AREDS 2 formula eye vitamin and mineral supplements and VYZULTA(R). Bausch Lomb Corporation is based in VAUGHAN, ON.
Revenue (Most Recent Fiscal Year) | $4.15B |
Net Income (Most Recent Fiscal Year) | $-260.00M |
PE Ratio (Current Year Earnings Estimate) | 34.16 |
PE Ratio (Trailing 12 Months) | 30.86 |
PEG Ratio (Long Term Growth Estimate) | 1.90 |
Price to Sales Ratio (Trailing 12 Months) | 1.60 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.09 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 10.67 |
Pre-Tax Margin (Trailing 12 Months) | -5.74% |
Net Margin (Trailing 12 Months) | -10.15% |
Return on Equity (Trailing 12 Months) | 3.36% |
Return on Assets (Trailing 12 Months) | 1.72% |
Current Ratio (Most Recent Fiscal Quarter) | 1.65 |
Quick Ratio (Most Recent Fiscal Quarter) | 1.01 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.70 |
Inventory Turnover (Trailing 12 Months) | 1.79 |
Book Value per Share (Most Recent Fiscal Quarter) | $19.72 |
Earnings per Share (Most Recent Fiscal Quarter) | $0.13 |
Earnings per Share (Most Recent Fiscal Year) | $0.73 |
Diluted Earnings per Share (Trailing 12 Months) | $-1.30 |
Exchange | NYSE |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
Common Shares Outstanding | 352.08M |
Free Float | 351.55M |
Market Capitalization | $7.17B |
Average Volume (Last 20 Days) | 0.67M |
Beta (Past 60 Months) | 0.48 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 0.15% |
Percentage Held By Institutions (Latest 13F Reports) | 11.07% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |